Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Responding to an FDA warning--geographic variation in the use of rosiglitazone.

× No keyword cloud information.

34 in total

Review 1. Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors: K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal: Br J Pharmacol Date: 2012-11 Impact factor: 8.739

2. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Authors: Ronac Mamtani; Kevin Haynes; Warren B Bilker; David J Vaughn; Brian L Strom; Karen Glanz; James D Lewis
Journal: J Natl Cancer Inst Date: 2012-08-09 Impact factor: 13.506

3. Drug vs class-specific black box warnings: does one bad drug spoil the bunch?

Authors: Stacie B Dusetzina; G Caleb Alexander
Journal: J Gen Intern Med Date: 2011-06 Impact factor: 5.128

4. Rosiglitazone: trials, tribulations and termination.

Authors: Andrew J Krentz
Journal: Drugs Date: 2011-01-22 Impact factor: 9.546

5. Changing prescribing patterns of type 2 diabetes medications from 2002-2010: an electronic health record-based evaluation.

Authors: Sanjeev N Mehta; Allison B Goldfine; Martin J Abrahamson; Richard DiVincenzo; Lori M B Laffel
Journal: J Diabetes Sci Technol Date: 2013-01-01

6. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?

Authors: Jason C Hsu; Dennis Ross-Degnan; Anita K Wagner; Fang Zhang; Christine Y Lu
Journal: Clin Ther Date: 2015-05-11 Impact factor: 3.393

7. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.

Authors: Domenico Motola; Carlo Piccinni; Chiara Biagi; Emanuel Raschi; Anna Marra; Giulio Marchesini; Elisabetta Poluzzi
Journal: Drug Saf Date: 2012-04-01 Impact factor: 5.606

Responding to an FDA warning--geographic variation in the use of rosiglitazone.